BT-001, AN ONCOLYTIC VACCINIA VIRUS ARMED WITH A TREG-DEPLETING HUMAN RECOMBINANT ANTI-CTLA4 ANTIBODY AND GM-CSF TO TARGET THE TUMOR MICROENVIRONMENT